Aug 3, 2026 | Biosimilars, Cost Savings, Drug costs, Pharmacy, Prescription, Rx Costs, Savings, Specialty Drugs
Specialty drug costs are projected to jump another 32% by 2028, according to the Pharmacy Strategies Group. While greater utilization remains the primary driver, lower-cost biosimilars can help pharmacy plans offset the increase. Biosimilars’ overall market share...
Jul 3, 2026 | Acquisition Cost Index (ACI) pricing, Biosimilars, Client Report, Drug costs, Formularies, MedBen Rx, Rx Costs, Specialty Drugs, Spending, Transparency
U.S. pharmaceutical expenditures rose 12.7% in 2025 to $915.2 billion, according to a recent analysis in the American Journal of Health-System Pharmacy. Utilization drove most of the growth, led by high-cost therapies such as tirzepatide, semaglutide, and apixaban....
May 4, 2026 | Biosimilars, Cost Savings, Drug costs, MedBen Rx, Rebates, Rx Costs, Savings
Specialty drugs account for more than half of total drug spend and are often the largest cost driver for employer pharmacy plans. A recent BenefitPRO article points to biosimilars as a practical solution — and for MedBen Rx clients, the effect is already clear, with...
Feb 23, 2026 | Biosimilars, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Specialty Drugs
Specialty medications continue to dominate pharmacy spend, now accounting for 52% of all U.S. pharmaceutical sales, according to a recent report from the Healthcare Distribution Alliance. With costs often reaching tens — or even hundreds — of thousands of dollars per...
Jan 12, 2026 | Acquisition Cost Index (ACI) pricing, Biosimilars, Brand Name Drugs, Drug costs, High-value formulary, MedBen Rx, News, Patient assistance, Pharmacogenomics, Pharmacy
Pharmaceutical manufacturers are planning to raise list prices on at least 350 brand-name medications in the United States beginning in 2026, up from 250 drugs last year, according to new data from health care research firm 3 Axis Advisors. These increases reflect...
Dec 30, 2025 | Benefits preservation, Biosimilars, Client Feedback, Client Surveys, Direct-to-Employer Contracting, Forensic claims review, Innovations, Kurt Harden, MedBen Employees, Self-funding, Spending, Third party administration
On behalf of the MedBen team, I wish you a happy and healthy new year, and thank you for your continued trust in MedBen. Our commitment remains to be the benefits partner that employers prefer, and we value the opportunity to serve you. In my 35 years with MedBen,...
